Previous 10 | Next 10 |
The optimism on Wall Street continued during Tuesday's session, as the Nasdaq led the major U.S. equity indices higher yet again. As a result, the S&P 500 recorded its first close above 4,600 since mid-January. While the overall market pushed higher, in part on hopeful signs out of peace ...
Gainers: IGM Biosciences (IGMS) +105%. China SXT Pharmaceuticals (SXTC) +73%. Clever Leaves Holdings (CLVR) +42%. MicroVision (MVIS) +31%. LianBio (LIAN) +26%. TC Biopharm (TCBP) +26%. Robinhood Markets (HOOD) +25%. Kinnate Biopharma (KNTE) +24%. Auddia (AUUD) +23%. Molecular Templates (...
Gainers: IGM Biosciences IGMS +37%. TRxADE HEALTH MEDS +21%. Ginkgo Bioworks DNA +14%. NexImmune NEXI +13%. BioSig Technologies (BSGM) +8%. Losers: NeoGenomics NEO -34%. Progenity PROG -25%. Aveanna Healthcare (AVAH) -21%. Kala Pharmaceuticals...
NeoGenomics (NEO) -29% on Q1 guidance cut; CEO to quit Progenity (PROG) -22% on Q4 earnings release. Stryve Foods (SNAX) -21% releases inaugural shareholder report. Kala Pharmaceuticals (KALA) -19% on Q4 earnings release. Lipocine (LPCN) -15% its partne...
Progenity (NASDAQ:PROG) has lost ~16% in the pre-market Tuesday after the molecular test maker reported lower than expected earnings with a decline in revenue for 4Q 2021. Revenue for the quarter dropped to $7.7M, indicating a ~21% YoY decline from the third quarter when the co...
Progenity, Inc. (PROG) Q4 2021 Earnings Conference Call March 28, 2022 04:30 PM ET Company Participants Chuck Padala - Managing Director of LifeSci Advisors Adi Mohanty - Chief Executive Officer Eric d'Esparbes - Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wai...
Progenity press release (NASDAQ:PROG): Q4 GAAP EPS of -$0.50 misses by $0.34. Revenue of $0.44M (+300.0% Y/Y). Shares -1.24%. For further details see: Progenity GAAP EPS of -$0.50 misses by $0.34, revenue of $0.44M
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics Clinical Programs with Initiation of Clinical Device Performance Study in Patients with Ulcerative Colitis Mana...
CYCC, DNA, EGLX, EYEN, HNRG, IONQ, LIDR, MBII, PLAY, OTCQX:PLNHF, PROG, RSLS, THMO, WYY, XOS, ZEV For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Monday's close
3 Reddit Penny Stocks to Add to Your Watchlist Right Now Are penny stocks a good investment? This is a question that has investors come to terms with on a daily basis. Some people believe that penny stocks are a great way to make money, while others believe that they are too risky. ...
News, Short Squeeze, Breakout and More Instantly...
Progenity Inc. Company Name:
PROG Stock Symbol:
NASDAQ Market:
Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18...
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday, July 17, 2024. The event will feature Bruce Sands, MD, MS (Icahn School of ...
Drug-device combination leverages Biora’s NaviCap ™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ab...